Dianthus Therapeutics
DNTHDianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation monoclonal antibodies and fusion proteins for severe autoimmune diseases.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Segments
By product
Competitors
By market cap
By net margin
Profile
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation monoclonal antibodies and fusion proteins for severe autoimmune diseases. The company's core value proposition lies in engineering therapies with extended half-lives and high selectivity to enable less frequent, self-administered subcutaneous injections that improve patient convenience and safety compared to existing treatments.
Dianthus positions itself as a developer of best-in-class, patient-friendly subcutaneous therapies that aim to replace more burdensome intravenous infusions and treatments with high infection risks.
Questions, answered.
- What is Dianthus Therapeutics's market cap?
- Dianthus Therapeutics (DNTH) has a market capitalization of $5.7B and trades on NASDAQ.
- Who are Dianthus Therapeutics's competitors?
- Dianthus Therapeutics's key competitors include Johnson & Johnson, Amgen, Cullinan Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Dianthus Therapeutics partner with?
- Dianthus Therapeutics's notable partners include Nanjing Leads Biolabs Co., Ltd., Tenacia Biotechnology (Hong Kong) Co., Limited, WuXi Biologics (Hong Kong) Limited, and others.
- Where is Dianthus Therapeutics headquartered?
- Dianthus Therapeutics is headquartered in United States of America and employs approximately 53 people. It has been publicly traded since 2023.